美股市场个股详情
ADAP Adaptimmune Therapeutics
- 1.100
- -0.050-4.35%
交易中 05/07 10:31 (美东)
2.81亿总市值-2037市盈率TTM
1.150最高价1.090最低价16.82万股成交量1.150今开1.150昨收18.68万成交额0.10%换手率亏损市盈率(静)2.56亿总股本2.05052周最高7.10市净率1.87亿流通值0.42052周最低--股息TTM1.70亿流通股21.570历史最高--股息率TTM5.22%振幅0.420历史最低1.110平均价1股每手
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
Adaptimmune Therapeutics股票讨论区
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade.
(Type of Cancer) Synovial Sarcoma : There are more than 50 different types of soft tissue sarcomas which are categorise...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
Abeona Therapeutics ( $Abeona Therapeutics(ABEO.US)$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ( $Rocket Pharmaceuticals(RCKT.US)$ )...
暂无评论